Monday, 06 December 2021 01:46 GMT

Kiadis to present at the Virtual European Biotech Investor Day 2020 Amsterdam Stock Exchange:KDS


(MENAFN- GlobeNewsWire - Nasdaq) Amsterdam, The Netherlands, June 17, 2020 – Kiadis Pharma N.V. ('Kiadis' or the 'Company') (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces that Kiadis will present at the Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq on Thursday, June 25, 2020 at 1:30pm EDT.

The presentation will be webcast live and may be accessed by visiting the "For Investors" section of the Company's website under the "Events and Presentations" tab at [To enable links contact MENAFN] A replay of the webcast will be available for 60 days.

Date: Thursday, June 25, 2020
Time: 1:30pm EDT
Webcast: [To enable links contact MENAFN]

Kiadis Contacts:

Kiadis :
Maryann Cimino, Sr. Manager, Corporate Affairs
Tel. +1 617 710 7305
Optimum Strategic Communications :
Mary Clark, Supriya Mathur
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514

Dutch Translation/Nederlandse vertaling

Kiadis Pharma nv ('Kiadis') (Euronext Amsterdam en Brussel: KDS) , een biofarmaceutisch bedrijf gericht op onderzoek in de klinische fase, kondigt aan dat het zal presenteren op de Virtual European Biotech Investor Day 2020 georganiseerd door Solebury Trout, Goodwin, Deutsche Bank en Nasdaq op donderdag 25 juni 2020 om 13.30 uur EDT.

De presentatie wordt live uitgezonden en kan worden bekeken via het tabblad 'For Investors' door op het subtabblad 'Events and Presentations' te klikken op de website van de onderneming: [To enable links contact MENAFN] Een herhaling van de webcast blijft 60 dagen beschikbaar.

Datum: Donderdag 25 juni 2020
Tijdstip: 13:30 uur EDT
Webcast: [To enable links contact MENAFN]

Dit persbericht vormt een vertaling van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd bepalend.

About Kiadis' K-NK-Cell Therapies
Kiadis' NK-cell programs consist of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. 

The Company's NK-cell PM21 particle technology enables improved ex vivo expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis' proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.

Kiadis is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. The Company is also developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT and provides functional, mature and potent NK-cells from a haploidentical family member. In addition, the Company has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. 

About Kiadis
Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at [To enable links contact MENAFN] .

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis' or, as appropriate, Kiadis' officers' current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.


MENAFN1706202000703653ID1100338246


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.